Search results
Results from the WOW.Com Content Network
Current Medicinal Chemistry is a peer-reviewed medical journal published by Bentham Science Publishers. The editor-in-chief is Atta-ur-Rahman, FRS (Kings College University of Cambridge Cambridge, UK). The journal covers developments in medicinal chemistry and rational drug design and publishes original research reports and review papers. [2]
Current Topics in Medicinal Chemistry is a biweekly peer-reviewed medical journal published by Bentham Science Publishers. It includes review articles on all aspects of medicinal chemistry, including drug design. The current editor-in-chief is Jia Zhou (University of Texas, Medical Branch).
Chemistry portal; Medicine portal; MedChemComm (in full: Medicinal Chemistry Communications) is a peer-reviewed scientific journal publishing original (primary) research and review articles on all aspects of medicinal chemistry, including drug discovery, pharmacology and pharmaceutical chemistry.
The poem concludes with the line "I have wasted my life." The line is one of the most highly regarded and widely debated lines in contemporary poetry, [2] [1] and has often been seen as having had cemented Wright's poetic legacy. [3] The line has been widely interpreted.
A long-lost tree species has new life after scientists planted a 1,000-year-old seed found in a cave in the Judean Desert in the 1980s during an archaeological dig. ... Lost biblical plant with ...
Reply to Li Shuyi (Chinese: 答李淑一) is a poem written on May 11, 1957 by Mao Zedong to Li Shuyi, a friend of Mao's first wife Yang Kaihui and the widow of the executed Communist leader Liu Zhixun. In the poem, "poplar" refers to Yang Kaihui, whose surname Yang means "poplar", and who also had been executed; and "willow" is the literal ...
Main page; Contents; Current events; Random article; About Wikipedia; Contact us; Help; Learn to edit; Community portal; Recent changes; Upload file
The phrase "drug design" is similar to ligand design (i.e., design of a molecule that will bind tightly to its target). [6] Although design techniques for prediction of binding affinity are reasonably successful, there are many other properties, such as bioavailability, metabolic half-life, and side effects, that first must be optimized before a ligand can become a safe and effictive drug.